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Objectives We sought to describe clinical and laboratory findings for a large cohort of patients with thienopyridine-
associated thrombotic thrombocytopenic purpura (TTP).
Background The thienopyridine derivatives, ticlopidine and clopidogrel, are the 2 most common drugs associated with TTP in
databases maintained by the U.S. Food and Drug Administration (FDA).
Methods Clinical reports of TTP associated with clopidogrel and ticlopidine were identified from medical records, pub-
lished case reports, and FDA case reports (n  128). Duration of thienopyridine exposure, clinical and laboratory
findings, and survival were recorded. ADAMTS13 activity (n  39) and inhibitor (n  30) were measured for a
subset of individuals.
Results Compared with clopidogrel-associated TTP cases (n  35), ticlopidine-associated TTP cases (n  93) were more
likely to have received more than 2 weeks of drug (90% vs. 26%), to be severely thrombocytopenic (84% vs.
60%), and to have normal renal function (72% vs. 45%) (p  0.01 for each). Compared with TTP patients with
ADAMTS13 activity 15% (n  13), TTP patients with severely deficient ADAMTS13 activity (n  26) were more
likely to have received ticlopidine (92.3% vs. 46.2%, p  0.003). Among patients who developed TTP 2 weeks
after thienopyridine, therapeutic plasma exchange (TPE) increased likelihood of survival (84% vs. 38%, p 
0.05). Among patients who developed TTP within 2 weeks of starting thienopyridines, survival was 77% with TPE
and 78% without.
Conclusions Thrombotic thrombocytopenic purpura is a rare complication of thienopyridine treatment. This drug toxicity ap-
pears to occur by 2 different mechanistic pathways, characterized primarily by time of onset before versus after
2 weeks of thienopyridine administration. If TTP occurs after 2 weeks of ticlopidine or clopidogrel therapy, thera-
peutic plasma exchange must be promptly instituted to enhance likelihood of survival. (J Am Coll Cardiol
2007;50:1138–43) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.093Medical Center, Pittsburgh, Pennsylvania; University of Texas Southwestern Medical
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September 18, 2007:1138–43 Thienopyridine-Associated TTP: SERF-TTP Updatehrombotic thrombocytopenic purpura (TTP) is a se-
ere, multisystem, thrombotic microangiopathy character-
zed by thrombocytopenia, microangiopathic hemolytic
nemia, renal dysfunction, neurologic abnormalities, and
ever (1). About one-fifth of TTP cases are associated with
harmaceuticals (2). The thienopyridine derivatives ticlopi-
ine and clopidogrel are the 2 most commonly reported to
he U.S. Food and Drug Administration (3–5) In 1998, we
eported 60 cases of ticlopidine-associated TTP, identifying
igh survival rates after therapeutic plasma exchange (TPE)
4,6). Clopidogrel, a newer thienopyridine derivative, differs
n structure from ticlopidine by one methoxycarbonyl group
7). It is now the second most commonly prescribed drug in
he U.S. In 2004, we described 39 patients with TTP
ssociated with clopidogrel use, highlighting frequent onset
ithin 2 weeks of drug initiation and high mortality rates
espite TPE (5). The manufacturer reported an incidence of
ne TTP case per 100,000 clopidogrel treated patients (8).
Marked advances in understanding of TTP pathophysi-
logy have occurred recently. One area relates to proteolytic
rocessing of plasma von Willebrand factor (VWF) and
haracterization of VWF-cleaving protease (VWF) and its
nhibitor, an immunoglobulin (Ig)G autoantibody (9,10). In
001, VWF-cleaving protease was identified as a metallo-
rotease ADAMTS13, belonging to the ADAMTS (a
isintegrin-like and metalloprotease with thrombospondin
ype 1 motif) family (11). Among idiopathic TTP patients,
any have ADAMTS13 deficiency caused by an inhibi-
ory IgG autoantibody. ADAMTS13 activity has been
easured for seven patients with ticlopidine-associated
TP, and ADAMTS13 deficiency and autoantibodies to
DAMTS13 were identified in all seven patients (12).
erein, we evaluated clinical, laboratory, and basic science
ndings for patients with thienopyridine-associated TTP,
epresenting the largest cohort of individuals with this rare
yndrome reported to date. Our aim is to identify clinically
mportant differences in presentation and outcome for patients
ith TTP associated with shorter- versus longer-term admin-
stration of ticlopidine and clopidogrel.
ethods
nvestigators with the RADAR (Research on Adverse Drug
vents and Reports) project identified cases of ticlopidine-
nd clopidogrel-associated TTP with the use of pharmaco-
igilance methods that have been described previously
eart, Lung, and Blood Institute (1R01 HL-096 717 and R01 CA102713 to Dr.
ennett, R01HL-079027 to Dr. Zheng, 1R01 HL-72917 to Dr. Sadler, and
54-HL077878 to Dr. Ortel); the Hematologic Diseases Branch, Centers for
isease Control and Prevention (U18 DD00014 to Dr. Ortel); the Northwestern
emorial Foundation (Dr. Bennett); the Goldberg Family Charitable Trust (Dr.
ennett); and the Japanese Ministry of Education, Culture, and Science and the
inistry of Health and Welfare of Japan for Blood Coagulation Abnormalities
H17-02 to Dr. Fujimura). Parts of these findings were presented orally at the
merican Heart Association Scientific Sessions in Chicago (November 2006).f
Manuscript received February 14, 2007; revised manuscript received April 5, 2007,
ccepted April 9, 2007.3–5,13,14). Thienopyridine-
ssociated TTP cases were iden-
ified from 4 sources: 1) volun-
ary reports submitted to Med-
atch, the Food and Drug Ad-
inistration’s Safety Information
nd Adverse Event Reporting Sys-
em (n  29); 2) published case
eries or reports from MED-
INE/PubMED, using MeSH
erms ticlopidine or clopidogrel, thrombotic microangiopathy,
nd TTP (n  40) (4,5,15,16); 3) direct queries of hematol-
gists and apheresis directors in 8 large apheresis centers in
eographically dispersed metropolitan areas (Charles Ben-
ett, MD, PhD, Chicago, Illinois; Joseph Kiss, MD,
ittsburgh, Pennsylvania; Thomas Ortel MD, PhD, and
icholas Bandarenko, MD, Raleigh-Durham, North Caro-
ina; Josh Levy, MD, and Nurit Begani, RN, Los Angeles,
alifornia; William Bell, MD, PHD, Baltimore, Maryland;
eo J McCarthy, MD, Indianapolis, Indiana; Jean Connors,
D, Boston, Massachusetts; and Joel Moake, MD, Hous-
on, Texas; n  42); and 4) a national referral laboratory in
apan (Yoshihiro Fujimura; n 17). A validated case report
orm was used to collect data on sociodemographic charac-
eristics, thienopyridine use, clinical data—platelet count
per mm3), hemoglobin level (g/dl), serum creatinine (mg/
l), neurologic findings (altered mental status, seizure,
troke, or coma)—use of TPE, and survival (4,5). Inclusion
riteria were thienopyridine use before the development of
hrombocytopenia (platelets 50,000/mm3) and microan-
iopathic hemolytic anemia on peripheral blood smear,
ithout the presence of any other identifiable cause, such as
isseminated intravascular coagulation, cancer, or pre-
clampsia. Those cases that did not fulfill or report all of the
equired inclusion criteria were excluded from analysis.
ssaying of ADAMTS13 activity. Basic laboratory stud-
es were conducted by investigators with the Surveillance
pidemiology and Risk Factors for TTP Study Group (17).
lasma was assayed for ADAMTS13 activity with 3 differ-
nt methods. Seventeen samples from a Japanese national
eferral laboratory compared the classic VWF multimer
ssay measuring the proteolysis of purified VWF into
leaved VWF fragments by sodium dodecyl sulfate agarose
el to a novel enzyme-linked immunoassay technique using
onoclonal antibodies directed against the decapeptide of
he VWF-A2 domain ending with the C-terminal edge
esidue Y1605, a cleaved VWF byproduct, and found 100%
oncordance in determining severe ADAMTS13 deficiency
18). Five samples were measured by collagen binding assay,
ased on the preferential binding of high-molecular-weight
orms of VWF to collagen (15,19). The measurement of
DAMTS13 activity in the remaining 17 plasma samples
as performed by measuring proteolysis of purified VWF
nto VWF fragments by gel electrophoresis (20). Previous
tudies have reported high levels of concordance in identi-
Abbreviations
and Acronyms
TPE  therapeutic plasma
exchange
TTP  thrombotic
thrombocytopenic purpura
VWF  von Willebrand
factorying persons with severe ADAMTS13 deficiency using
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Thienopyridine-Associated TTP: SERF-TTP Update September 18, 2007:1138–43hese methods for assaying ADAMTS13 levels (21). The
nhibitory activity of the IgG autoantibody was determined
y mixing TTP plasma samples at various dilutions with
ormal plasma and measuring the protease activity of the
ixture, as previously reported and described (20).
tatistical analysis. Bivariate analysis of factors associated
ith administration of ticlopidine versus clopidogrel, and
horter- versus longer-term thienopyridine administration,
ere evaluated with a nonparametric exact methodology
alled optimal discriminant analysis. Used to analyze binary
ttributes, optimal discriminant analysis yields results iso-
orphic with the Fisher exact test and, when used to
nalyze ordinal attributes, optimal discriminant analysis
dentifies a threshold value that explicitly maximizes classi-
cation accuracy (22). A cut point of 2 weeks or less was
etermined a priori to define short-term thienopyridine
dministration based on findings reported previously (3–5).
or the subset of patients for whom ADAMTS13 activity
evels were measured, optimal discriminant analysis was
sed to evaluate clinical and laboratory findings associated
ith severe ADAMTS13 deficiency, characterized as activ-
ty levels 15% of normal human plasma as in prior studies
23). However, our findings were qualitatively similar if a
ut point of 5% was used, a threshold that was used in some
tudies (23). A multivariate nonlinear model for predicting
urvival from TTP was obtained via hierarchically optimal
lassification tree analysis (21,24). Finally, survival analysis
as conducted with Cox proportional hazards survival
nalysis, with log-rank statistics used to test for differences
n the survival outcomes, and Kaplan-Meier analysis for
lotting survival curves.
esults
etween 1998 and 2005, 93 ticlopidine- and 35
lopidogrel-associated TTP cases were identified (Table
). Patients with ticlopidine- and clopidogrel-associated
TP were similar in age (mean 64.2 vs. 58.1 years) and
ender (male 53.4% vs. 54.3%) but differed significantly
n duration of thienopyridine exposure prior to develop-
haracteristics of Thienopyridine-Associated TTP Cases
Table 1 Characteristics of Thienopyridine-Associated TTP Case
All Patients
(n  128)
Thienopyridine
Rx <14 Days
(n  35)
Thie
Rx
(
Mean age, yrs (SD) 62.4 (13.9) 59.8 (13.2) 63
Male 53.7% 57.1%
Thienopyridine Rx 14 days 27.3% —
Thienopyridine Rx 14 days 72.7% —
ADAMTS13 deficient 66.7% 44.4%
Platelet count 20,000/mm3 77.3% 65.7%†
Creatinine 2.5 mg/dl 35.6% 41.9%
Abnormal neurologic findings 29.1% 33.3%
Received TPE 76.6% 74.3%
Survival 74.2% 77.1%p  0.05; †p  0.07.
Rx  treatment; TPE  therapeutic plasma exchange; TTP  thrombotic thrombocytopenic purpura.ent of TTP (p  0.002) (Fig. 1A). In comparison with
atients with clopidogrel-associated TTP, those with
iclopidine-associated TTP were more likely to have
eceived more than 2 weeks of a thienopyridine before
TP (90.3% vs. 25.7%, p  0.0001) and to present with
evere thrombocytopenia (platelet count 20  109/l)
83.9% vs. 60.0%, p  0.005) but less likely to have renal
nsufficiency (27.8% vs. 55.2%, p  0.02) (Table 1).
We evaluated clinical findings, outcomes, and plasma
DAMTS13 activity for 39 thienopyridine-associated TTP
atients (Table 1). In comparison with TTP patients with
DAMTS13 activity 15%, those with severely deficient
DAMTS13 activity were more likely to have received
iclopidine (92.3% vs. 46.2%, p  0.003) and to be severely
hrombocytopenic (96.2% vs. 38.5%, p  0.001) (Table 1)
nd had a trend toward developing TTP after longer periods
f drug exposure (Fig. 1B). Among 30 patients with
hienopyridine-associated TTP and plasma available for
ssays of autoantibody to ADAMTS13, none with normal
DAMTS13 activity had detectable levels of inhibitor,
hereas every patient with severe ADAMTS13 deficiency
ad IgG autoantibodies that inhibited ADAMTS13 activity
p  0.0001). Survival was greater among thienopyridine-
ssociated TTP patients with deficient ADAMTS13 activ-
ty levels who underwent TPE compared with those who
id not (90.9% vs. 50.0%, p 0.05). Among six ticlopidine-
ssociated and seven clopidogrel-associated TTP patients
hose ADAMTS13 levels were15%, 12 underwent TPE,
nd only 7 (58.3%) survived.
Overall, the mortality rate for patients with thienopyridine-
ssociated TTP was 25.8%. Univariate associations identified
everal characteristics significantly associated with an increased
ortality risk for the total sample, including abnormal neuro-
ogic status (p  0.02), serum creatinine 2.5 mg/dl (p 
.04), and not receiving TPE (p  0.0006). Among patients
ho developed TTP after 2 weeks of thienopyridine expo-
ure, survival was 2.2-fold greater when treated with TPE
84% vs. 38%, p 0.05). Among patients who developed TTP
ithin 2 weeks of starting thienopyridines, survival was 77%
idine
ays
3)
Ticlopidine
(n  93)
Clopidogrel
(n  35)
ADAMTS13
Deficient
(n  26)
ADAMTS13
Nondeficient
(n  13)
.1) 64.2 (12.9) 58.1 (15.3) 67.1 (12.0) 60.3 (20.2)
53.4% 54.3% 46.2% 61.5%
9.7%* 74.3%* 15.4% 38.5%
90.3% 25.7% 84.6% 61.6%
80%* 22.2%*
† 83.9%* 60.0%* 96.2%* 38.5%*
27.8%* 55.2%* 26.9% 46.2%
27.8% 32.3% 19.2% 15.4%
74.2% 82.9% 84.6% 92.3%
75.3% 71.4% 84.6% 61.5%s
nopyr
>14 D
n  9
.4 (14
52.3%
—
—
73.3%
81.7%
32.9%
27.3%
77.4%
73.1%
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September 18, 2007:1138–43 Thienopyridine-Associated TTP: SERF-TTP Updateith TPE and 78% without. A multivariate classification tree
nalysis model revealed that among thienopyridine-associated
TP patients who received TPE, those patients with
DAMTS13 activity levels 15% at the time of diagnosis of
TP were 4-fold more likely to die (41.9% vs. 9.1%, p 
.036).
iscussion
ur study identifies distinct clinical, laboratory, and out-
ome differences between ticlopidine- and clopidogrel-
ssociated TTP. More than 90% of the ticlopidine-
ssociated TTP cases develop after more than 2 weeks of
hienopyridine use. Among these patients, severe thrombo-
ytopenia and preserved renal function at diagnosis is
ommon, ADAMTS13 activity levels are frequently 15%,
nd survival is 86% if TPE is administered versus 46% if
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Figure 1 Duration of Thienopyridine
Exposure Prior to TTP Onset
(A) Thienopyridine-associated thrombotic thrombocytopenic purpura (TTP)
onset: ticlopidine versus clopidogrel (p  0.0016). (B) Thienopyridine-associ-
ated TTP onset: ADAMTS13 deficient versus ADAMTS13 nondeficient (p 
0.05).PE is not used. These findings are similar to those
*eported previously for idiopathic TTP cases with severely
eficient ADAMTS13 activity levels (16,23,25). In con-
rast, three-quarters of the clopidogrel-associated TTP cases
evelop after 2 weeks or less of thienopyridine use. These
atients are characterized by mild thrombocytopenia and
enal insufficiency at diagnosis, ADAMTS13 activity
evels 15%, and survival rates that are similar with
ersus without TPE (72.4% and 66.7%), findings that are
imilar to those reported previously for TTP cases with
DAMTS13 activity levels 25%. Our findings suggest 2
echanistic pathways for thienopyridine-associated TTP,
n immunologic pathway associated with more than 2 weeks
f thienopyridine use and a nonimmunologic pathway
ssociated with 2 weeks or less of thienopyridine use. In
nterpreting our study, several factors should be considered.
The results for patients with severe ADAMTS13 defi-
iency and thienopyridine-associated TTP reinforce previ-
us observations for patients with ticlopidine-associated
TP. Tsai et al. (12) reported 7 ticlopidine-associated TTP
atients who had severe ADAMTS13 deficiency and inhib-
tors to ADAMTS13 at diagnosis, all of whom responded
apidly to TPE. The use of TPE in these patients may result
n removal of ADAMTS13 inhibitors and ultra-large VWF
ultimers, replenishment of ADAMTS13 and VWF, and
eduction of cytokines that induce endothelial cell damage
nd platelet activation (26). Our study also describes cases of
hienopyridine-associated TTP cases who do not have
evere ADAMTS13 deficiency and whose survival was not
nfluenced by TPE. Preservation of ADAMTS13 activity
as been described in patients with post-transplantation
hrombotic microangiopathy (27,28) who frequently present
ith renal insufficiency, moderate thrombocytopenia, and
igh mortality rates despite TPE. Others have described
TP-like findings among persons with factor V Leiden
utation (29).
Our study has implications for patient safety. First, for
he rare individual with a drug-eluting coronary artery stent
ho develops TTP after the administration of clopidogrel
nd for whom discontinuation of thienopyridine-therapy
ould be catastrophic, ticlopidine challenge can be consid-
utcomes for Ticlopidine- andlopidogrel-Associated TTP Cases
Table 2 Outcomes for Ticlopidine- andClopidogrel-Associated TTP Cases
Survival
With TPE, %
Survival
Without TPE, %
All patients (n  128)* 81.6 50.0
Ticlopidine (N  93) * 85.5 45.8
Ticlopidine Rx 14 days (n  9) 100.0 100.0
Ticlopidine Rx 14 days (n  84) 84.1* 38.1*
Clopidogrel (N  35) 72.4 66.7
Clopidogrel Rx 14 days (n  26) 70.0 66.7
Clopidogrel Rx 14 days (n  9) 77.8 —
Thienopyridine Rx 14 days (n  35) 76.9 77.8
Thienopyridine Rx 14 days (n  93) 83.3* 38.1*p  0.05 (for comparison of survival with TPE vs. without TPE).
Abbreviations as in Table 1.
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Thienopyridine-Associated TTP: SERF-TTP Update September 18, 2007:1138–43red. For most patients with clopidogrel-associated TTP,
ur findings suggest that the toxicity is unlikely to be
mmunologic in etiology. Patel et al. (30) recently described
case report of a patient with a history of clopidogrel-
ssociated TTP who successfully received ticlopidine ther-
py following implantation of a drug eluting coronary artery
tent. Two years had elapsed between the development of
lopidogrel-associated TTP and ticlopidine initiation. Sec-
nd, the RADAR program has developed new approaches
o drug safety that build on close collaborations with referral
enters that have developed novel assays (13). We identified
large part of our cohort by querying hematologists or
edical directors of TPE centers who were collaborating in
prospective case-control epidemiologic study or who sent
lasma samples for possible TTP cases to a referral center
or measurement of ADAMTS13 activity. Similar collabo-
ations with a referral center that developed novel assays for
etecting antierythropoietin-associated antibodies facilitated
he identification of another drug-associated toxicity,
rythropoietin-associated pure red cell aplasia (31).
tudy limitations. The limitations of our study should be
dentified. First, thienopyridine-associated TTP is un-
oubtedly a rare diagnosis, limiting our ability to obtain
lasma from large numbers of patients. Second, although
linical information on most of the cases reported herein
ave been reported previously, these studies did not directly
ompare TTP cases according to drug (ticlopidine vs.
lopidogrel) or the duration of thienopyridine administra-
ion (4,5). Also, previous studies included information on
DAMTS13 activity levels and ADAMTS13 inhibitors for
nly 10 patients with thienopyrindine-associated TTP.
hird, the demographic characteristics of the TTP patients
n this study differ from those reported in case series of TTP
atients. In particular, in comparison with thienopyridine-
ssociated TTP patients, patients in the study of Vesely
t al. (24) were younger (mean 35 to 50 vs. 60 to 65 years)
nd more likely to be female (80% vs. 45%) (16,17,25) and,
herefore, there continues to be uncertainty about causal
echanisms for clopidogrel, primarily because clopidogrel-
ssociated TTP occurs markedly less often than ticlopidine-
ssociated TTP (32–35).
onclusions
hrombotic thrombocytopenic purpura is a rare complica-
ion of thienopyridine treatment. This drug toxicity appears
o occur by 2 different mechanistic pathways, characterized
rimarily by time of onset of  versus 2 weeks of
hienopyridine administration. If TTP occurs after 2 weeks
f ticlopidine or clopidogrel therapy, TPE must be
romptly instituted to enhance the likelihood of survival.
cknowledgments
he authors gratefully acknowledge Han Mou Tsai, MD,
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